What we know about the B1617 variant from India as COVID-19 sweeps South Asia

What we know about the B1617 variant from India as COVID-19 sweeps South Asia

Coronavirus disease (COVID-19) outbreak in New Delhi
Beds are seen inside a Gurudwara (Sikh Temple) converted into a COVID-19 care facility in New Delhi, India on May 5, 2021. (Photo: REUTERS/Adnan Abidi)

NEW DELHI: India has recorded the world's sharpest spike in coronavirus infections this month, with political and financial capitals New Delhi and Mumbai running out of hospital beds, oxygen and medicines.

Scientists are studying what led to the unexpected surge, and particularly whether a variant of the novel coronavirus first detected in India is to blame. 

READ: Virus variant from India 'concerning' as infections could spread 'quickly and widely', says Gan Kim Yong

READ: COVID-19 virus variants from India detected in Singapore: What you need to know

The variant, named B1617, has been reported in 17 countries, raising global concern. 

Here are the basics:

WHAT IS THE B1617 VARIANT FROM INDIA?

The B1617 variant contains two key mutations to the outer "spike" portion of the virus that attaches to human cells, said senior Indian virologist Shahid Jameel.

The World Health Organization (WHO) said the predominant lineage of B1617 was first identified in India last December, although an earlier version was spotted in October 2020.

On May 10, the WHO classified it as a "variant of concern", which also includes variants first detected in Britain, Brazil and South Africa. Some initial studies showed the B1617 variant from India spreads more easily.

"There is increased transmissibility demonstrated by some preliminary studies," Maria Van Kerkhove, WHO's technical lead on COVID-19, said, adding it needs more information about the B1617 variant from India to understand how much of it is circulating.

ARE VARIANTS DRIVING THE SURGE IN CASES?

It's hard to say.

Laboratory-based studies of limited sample size suggest potential increased transmissibility, according to the WHO.

The picture is complicated because the highly transmissible B117 variant first detected in the UK is behind spikes in some parts of India. 

In New Delhi, UK variant cases almost doubled during the second half of March, according to Sujeet Kumar Singh, director of the National Centre for Disease Control. 

The B1617 variant from India, though, is widely present in Maharashtra, the country's hardest-hit state, Singh said.

READ: Philippines records first two cases of Indian COVID-19 variant

READ: Pregnant woman is Thailand's first COVID-19 case with B1617 variant from India

Prominent US disease modeller Chris Murray, from the University of Washington, said the sheer magnitude of infections in India in a short period of time suggests an "escape variant" may be overpowering any prior immunity from natural infections in those populations.

"That makes it most likely that it’s B1617," he said. But Murray cautioned that gene sequencing data on the coronavirus in India is sparse, and that many cases are also being driven by the UK and South African variants.

Carlo Federico Perno, Head of Microbiology and Immunology Diagnostics at Rome's Bambino Gesù Hospital, said the B1617 variant from India couldn't alone be the reason for India's huge surge, pointing instead to large social gatherings.

Prime Minister Narendra Modi has been criticised for allowing massive political rallies and religious festivals which have been super-spreader events in recent weeks.

DO VACCINES STOP IT?

One bright spot is that vaccines may be protective. White House chief medical adviser Anthony Fauci said that preliminary evidence from lab studies suggest Covaxin, a vaccine developed in India, appears capable of neutralising the variant.

Public Health England said it was working with international partners but that there is currently no evidence that the B1617 variant from India and two related variants cause more severe disease or render the vaccines currently deployed less effective.

"We don't have anything to suggest that our diagnostics, our therapeutics and our vaccines don't work. This is important," said Van Kerkhove at WHO. 

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: Reuters/ic

Bookmark